These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32153216)

  • 1. Exploration of baseline patient-reported side effect bother from cancer therapy.
    Roydhouse JK; King-Kallimanis BL; Roy P; Weinstock C; Krol D; Daniels SR; Suzman DL; Beaver JA; Kluetz PG
    Clin Trials; 2020 Jun; 17(3):332-337. PubMed ID: 32153216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.
    Pearman TP; Beaumont JL; Mroczek D; O'Connor M; Cella D
    Cancer; 2018 Mar; 124(5):991-997. PubMed ID: 29131323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials.
    Trask PC; Holt T; Pearman T
    Qual Life Res; 2023 Sep; 32(9):2601-2615. PubMed ID: 37119353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer.
    Gharzai LA; Mierzwa ML; Stepan KO; Cella D; Peipert JD
    Support Care Cancer; 2024 Aug; 32(9):575. PubMed ID: 39107440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale.
    Kaiser K; Beaumont JL; Webster K; Yount SE; Wagner LI; Kuzel TM; Cella D
    Cancer Med; 2015 May; 4(5):690-8. PubMed ID: 25619758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma.
    Peipert JD; Zhao F; Lee JW; Shen SE; Ip E; O'Connell N; Carlos RC; Graham N; Smith ML; Gareen IF; Raper PJ; Weiss M; Kumar SK; Rajkumar SV; Cella D; Gray R; Wagner LI
    JAMA Netw Open; 2024 Mar; 7(3):e243854. PubMed ID: 38536173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients.
    Griffiths P; Peipert JD; Leith A; Rider A; Morgan L; Cella D; Cocks K
    Support Care Cancer; 2022 Apr; 30(4):3613-3623. PubMed ID: 35031830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyzing patient-reported outcome data when completion differs between arms in open-label trials: an application of principal stratification.
    Roydhouse JK; Gutman R; Bhatnagar V; Kluetz PG; Sridhara R; Mishra-Kalyani PS
    Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1386-1394. PubMed ID: 31410963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.
    Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C
    Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
    Luo X; Cappelleri JC; Cella D; Li JZ; Charbonneau C; Kim ST; Chen I; Motzer RJ
    Value Health; 2009 Jun; 12(4):580-6. PubMed ID: 19900256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy.
    King-Kallimanis BL; Kanapuru B; Blumenthal GM; Theoret MR; Kluetz PG
    Semin Oncol; 2018 Aug; 45(4):201-209. PubMed ID: 30482633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
    Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
    Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
    Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
    Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.
    Cella D; Motzer RJ; Rini BI; Cappelleri JC; Ramaswamy K; Hariharan S; Arondekar B; Bushmakin AG
    Value Health; 2018 Dec; 21(12):1413-1418. PubMed ID: 30502785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA.
    Ribbands A; Boytsov N; Bailey A; Gorsh B; Luke E; Lambert A
    Support Care Cancer; 2023 Jun; 31(6):371. PubMed ID: 37268868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy for prostate cancer - Does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial.
    Tøndel H; Lund JÅ; Lydersen S; Wanderås AD; Aksnessæther B; Jensen CA; Kaasa S; Solberg A
    Radiother Oncol; 2018 Feb; 126(2):229-235. PubMed ID: 29398152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Educational Program to Help Patients Manage Androgen Deprivation Therapy Side Effects: Feasibility, Acceptability, and Preliminary Outcomes.
    Wibowo E; Wassersug RJ; Robinson JW; Santos-Iglesias P; Matthew A; McLeod DL; Walker LM
    Am J Mens Health; 2020; 14(1):1557988319898991. PubMed ID: 32024430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
    Basch E; Rogak LJ; Dueck AC
    Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.
    Hanlon AL; Watkins Bruner D; Peter R; Hanks GE
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.